If the LUX-Head & Neck 1 trial meets its primary endpoint , it will demonstrate the ability of afatinib to elicit an improved treatment benefit versus a commonly used chemotherapy agent in the second-line treatment of R/M HNSCC patients who have failed on first-line platinum-based therapy , confirm the clinical efficacy of afatinib observed in the Phase II proof-of-concept study , and establish a new standard of care for this patient population .